Total Payments
$2,702
2024 Payments
$866.89
Companies
10
Transactions
152
Medicare Patients
2,415
Medicare Billing
$259,893
Payment Breakdown by Category
Food & Beverage$2,571 (95.1%)
Education$131.63 (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,571 | 147 | 95.1% |
| Education | $131.63 | 5 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $980.97 | 48 | $0 (2024) |
| ViiV Healthcare Company | $452.32 | 36 | $0 (2024) |
| ABBVIE INC. | $431.46 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $358.59 | 22 | $0 (2024) |
| Allergan, Inc. | $139.10 | 11 | $0 (2020) |
| PFIZER INC. | $102.46 | 1 | $0 (2018) |
| AIMMUNE THERAPEUTICS, INC. | $77.27 | 3 | $0 (2024) |
| Astellas Pharma US Inc | $72.00 | 1 | $0 (2018) |
| Ferring Pharmaceuticals Inc. | $66.56 | 4 | $0 (2024) |
| Mylan Pharmaceuticals Inc. | $21.74 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $866.89 | 56 | Gilead Sciences, Inc. ($323.28) |
| 2023 | $975.18 | 55 | Gilead Sciences, Inc. ($585.47) |
| 2022 | $199.55 | 12 | Gilead Sciences, Inc. ($72.22) |
| 2021 | $76.77 | 5 | AbbVie Inc. ($43.14) |
| 2020 | $39.61 | 3 | Allergan, Inc. ($25.83) |
| 2019 | $87.30 | 6 | Merck Sharp & Dohme Corporation ($74.63) |
| 2018 | $391.36 | 10 | AbbVie, Inc. ($114.57) |
| 2017 | $65.81 | 5 | Allergan Inc. ($35.84) |
All Payment Transactions
152 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: HIV | ||||||
| 12/16/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/12/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: GI | ||||||
| 11/21/2024 | ABBVIE INC. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.88 | General |
| 11/14/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: HIV | ||||||
| 10/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.29 | General |
| 10/23/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $30.33 | General |
| Category: GI | ||||||
| 10/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: HIV | ||||||
| 10/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $1.67 | General |
| Category: HIV | ||||||
| 10/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.71 | General |
| 10/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.29 | General |
| 09/23/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: HIV | ||||||
| 09/16/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/09/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/09/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $3.15 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/29/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: HIV | ||||||
| 08/28/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: GI | ||||||
| 08/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.05 | General |
| 08/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.25 | General |
| 08/19/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $3.98 | General |
| Category: HIV | ||||||
| 07/31/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/25/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: HIV | ||||||
| 07/18/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 559 | 976 | $118,404 | $61,721 |
| 2022 | 8 | 599 | 1,078 | $122,704 | $63,102 |
| 2021 | 6 | 586 | 1,012 | $123,672 | $64,364 |
| 2020 | 7 | 671 | 1,145 | $133,896 | $70,706 |
Total Patients
2,415
Total Services
4,211
Medicare Billing
$259,893
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 176 | 200 | $38,448 | $20,451 | 53.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 138 | 423 | $30,804 | $16,556 | 53.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 70 | 134 | $15,678 | $8,310 | 53.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 87 | $12,180 | $5,978 | 49.1% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 72 | 74 | $9,214 | $4,759 | 51.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 32 | $6,400 | $3,044 | 47.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $3,640 | $1,611 | 44.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $2,040 | $1,011 | 49.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 184 | 208 | $42,432 | $22,476 | 53.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 149 | 472 | $27,406 | $14,636 | 53.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 88 | 167 | $17,869 | $9,473 | 53.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 85 | $11,900 | $5,441 | 45.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 63 | 65 | $9,787 | $5,113 | 52.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 25 | $5,000 | $2,399 | 48.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 28 | $3,920 | $1,496 | 38.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $2,860 | $1,318 | 46.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 14 | 17 | $1,530 | $751.87 | 49.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 210 | 245 | $49,980 | $26,579 | 53.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 143 | 392 | $22,736 | $12,132 | 53.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 91 | 191 | $20,437 | $11,021 | 53.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 57 | $11,400 | $5,492 | 48.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 62 | 81 | $11,340 | $5,458 | 48.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 29 | 29 | $4,379 | $2,335 | 53.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 17 | $3,400 | $1,347 | 39.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 246 | 270 | $55,080 | $30,024 | 54.5% |
About Dr. Michael Blank, MD
Dr. Michael Blank, MD is a Infectious Disease healthcare provider based in Sandusky, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710926985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Blank, MD has received a total of $2,702 in payments from pharmaceutical and medical device companies, with $866.89 received in 2024. These payments were reported across 152 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($2,571).
As a Medicare-enrolled provider, Blank has provided services to 2,415 Medicare beneficiaries, totaling 4,211 services with total Medicare billing of $259,893. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Sandusky, OH
- Active Since 06/05/2006
- Last Updated 09/11/2012
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1710926985
Products in Payments
- DOVATO (Drug) $405.39
- AVYCAZ (Drug) $278.65
- DIFICID (Drug) $187.46
- DALVANCE (Drug) $121.60
- Humira (Biological) $114.57
- Descovy (Drug) $112.50
- EUCRISA (Drug) $102.46
- VOWST (Biological) $77.27
- ZERBAXA (Drug) $68.52
- REBYOTA (Biological) $66.56
- TEFLARO (Drug) $55.74
- APRETUDE (Biological) $46.93
- Veklury (Drug) $37.89
- NOXAFIL (Drug) $33.97
- PIFELTRO (Drug) $33.07
- Symfi Lo (Drug) $21.74
- RECARBRIO (Drug) $18.34
- PREVYMIS (Drug) $17.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.